Are Dividends Built To Last At AstraZeneca plc And BP plc?

How safe are AstraZeneca plc’s (LON: AZN) and BP plc’s (LON: BP) Dividends?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Some dividends have staying power. Companies delivering enduring dividends tend to back such often-rising payouts with robust business and financial achievement.

Fragile dividends, meanwhile, arise because of weaker operational and financial characteristics. Those are the dividends to avoid. However, fragile dividends often tempt us because of high dividend yields.

How to tell the difference

Under the spotlight today, two FTSE 100 firms: AstraZeneca (LSE: AZN) the pharmaceutical supplier and BP (LSE: BP) the oil giant.

Should you invest £1,000 in British American Tobacco right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if British American Tobacco made the list?

See the 6 stocks

These firms operate in different sectors, but they both have a reasonable dividend yield. At the recent share price of 4320p, AstraZeneca’s forward yield for 2016 is 4.3%. At 332p, BP’s is 7.8%.

Let’s run some tests to gauge business and financial quality, and score performance in each test out of a maximum five.

  1. Dividend record

Both firms maintained dividend payments over the past five-year trading period:

Ordinary dividends

2011

2012

2013

2014

2015

AstraZeneca (cents)

280

280

280

280

280 (e)

BP  (cents)

29

34

37

39.5

40 (e)

AstraZeneca’s dividend has been flat, but BP looks set to move its payment forward by 38% if 2015’s fourth quarter payment keeps up the established pattern. However, there is some doubt about whether the dividend is sustainable, due to the continuing low price of oil.

Both firms managed to maintain payments over the last few years. So, for their dividend records, I’m scoring AstraZeneca 2/5 and BP  4/5.

  1. Dividend cover

AstraZeneca expects its 2016 adjusted earnings to cover its dividend around 1.4 times. BP expects cover from earnings of just 0.9 times, which makes on-going dividend payments look vulnerable.

Both firms are running thin cover from adjusted earnings. I’m more comfortable with cover of around two times earnings. Of course, cash pays dividends, so it’s worth digging deeper into how well, or poorly, companies cover their dividend payouts with free cash flow.

On dividend cover from earnings, I’m scoring AstraZeneca  2/5 and BP 1/5.  

  1. Cash flow

Dividend cover from earnings means little if cash flow doesn’t support profits.

Here are the firms’ recent records on cash flow compared to profits:

AstraZeneca

2010

2011

2012

2013

2014

Operating profit ($m)

11,494

12,795

8,148

3,712

2,137

Net cash from operations ($m)

10,680

7,821

6,948

7,400

7,058

BP

 

 

 

 

 

Operating profit ($m)

(9,140)

33,001

14,157

27,803

2,197

Net cash from operations ($m)

13,616

22,154

20,479

21,100

32,754

Generally, both businesses see there cash flow support profits well. I’m scoring both firms 4/5 for cash flow.

  1. Level of gross debt

Interest payments on borrowed money compete with dividend payments for incoming cash flow. That’s why big debts are undesirable in dividend-led investments.

At the last count, BP’s borrowings were around 1.75 times the size of its net cash from operations, which seems manageable. AstraZeneca’s is even better at about 1.5 times its last-reported net cash from operations figure.

My attitude to debt in mature companies is quite harsh — I’m old-fashioned and believe they are better off without it — so, for their debt positions, BP gets 2/5 and AstraZeneca scores 3/5

  1. Degree of cyclicality

AstraZeneca’s share price moved from around 3,000p at the beginning of 2011 to 4,320p or so today, handing investors a 44% capital gain over the period to add to income from dividends.

BP slipped from around 500p at the start of 2011 to around 332p today, erasing investor dividend gains, and then some.

Those share-price movements act as a clue to the degree of cyclicality inherent in each sector. At one end of the cyclicality scale, we have BP, a business joined at the hip with macro-cycles and with little control over its own selling prices as the price of oil dances up and down to the tune of supply and demand.

At the other end of the cyclicality scale sits AstraZeneca, a firm well placed in a consumable market with high barriers to entry, and a structural trend locked on a course of rising demand. Patent expiry issues move in cycles, but they are cycles the firm may control by keeping up investment in research and development.

Of the two firms, in terms of cyclicality AstraZeneca best supports a long-term dividend-led investment strategy. I’m scoring BP 1/5 and AstraZeneca 4/5.

Putting it all together

Here are the final scores for these firms:

 

AstraZeneca

BP

Dividend record

2

4

Dividend cover

2

1

Cash flow

4

4

Level of gross debt

3

2

Degree of cyclicality

4

1

Total score out of 25

15

12

Neither firm is perfect but I’m inclined to put greater weight on some factors over others. For example, BP’s finances look reasonable after a period of relative prosperity, which boosts some of the scores. The current year’s results are not in yet, though, and the persistent low price of oil will surely affect the firm’s dividend outlook from here. Looking at BP’s share-price performance the effects of cyclicality are difficult to predict.

AstraZeneca’s operations, though, seem far more stable. The dynamics of the pharmaceutical sector gives AstraZeneca a fair chance of restoring its profitability from here, which could work well for a long-term, dividend-led investment in the firm over the coming years.

Should you buy British American Tobacco shares today?

Before you decide, please take a moment to review this first.

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

£10,000 invested in Lloyds shares on 7 April is already worth…

After a dip in early April, Lloyds shares are back to their 30%+ year-to-date gain in 2025. And analysts are…

Read more »

US Stock

What I’d look to buy as the US stock market heads for the worst month since 1932

Jon Smith sifts through the US stock market to try and find some ideas that have fallen in value recently…

Read more »

Growth Shares

Prediction: I think £1,000 invested in this UK stock could double by 2030

Jon Smith runs through a FTSE 250 stock with a market cap just over £1bn that he feels has the…

Read more »

Investing Articles

With £10k in savings, here’s how an investor could target a second income of £500 a month

£10k in savings could be the foundation needed towards a powerful second income. Our writer details some steps necessary to…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing For Beginners

£1k invested in the FTSE 100 on ‘Liberation Day’ is now worth…

Jon Smith talks about the volatility in the FTSE 100 in the weeks since the tariff announcements and flags up…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Barclays’ share price is down 7% from March, so is now the right time for me to buy?

Barclays’ share price has dipped recently, which could mean a bargain to be had. I took a deep dive into…

Read more »

Investing Articles

Down 13% since March, does this rising FTSE 250 defence star look an unmissable buy for me?

The FTSE 250 is currently home to many of the big stock stars of tomorrow and I think this high-tech…

Read more »

Investing Articles

Should I buy Aston Martin shares for my ISA while they’re under 70p?

With Aston Martin's shares down hugely across multiple time frames, this writer is wondering if he should snap up some…

Read more »